Current Report Filing (8-k)
November 12 2020 - 4:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________________________
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
November 12, 2020
________________________________
CAPRICOR THERAPEUTICS, INC.
(Exact name of Registrant as Specified
in its Charter)
Delaware
|
|
001-34058
|
|
88-0363465
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
8840 Wilshire Blvd., 2nd Floor, Beverly
Hills, CA
(Address of principal executive offices)
|
|
90211
(Zip Code)
|
(310) 358-3200
(Registrant’s telephone number,
including area code)
Not Applicable
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange
Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ¨
Title of Each Class
|
|
Trading Symbol(s)
|
|
Name of Each Exchange on Which Registered
|
Common Stock, par value $0.001 per share
|
|
CAPR
|
|
The Nasdaq Capital Market
|
Item 2.02 Results of Operations and Financial Condition.
|
On November 12, 2020, Capricor Therapeutics,
Inc., a Delaware corporation (the “Company”), issued a press release announcing its financial results for the quarter
ended September 30, 2020. A copy of the press release is being furnished herewith as Exhibit 99.1 to this Current Report on Form
8-K.
The information under Item 2.02 of this
Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be filed for purposes
of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the
liabilities of that section, nor shall it be incorporated by reference into any of the Company’s filings under the Securities
Act of 1933, as amended, or the Exchange Act, unless expressly set forth as being incorporated by reference into such filing.
Item 9.01
|
Financial Statements and Exhibits.
|
(d) Exhibits
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto
duly authorized.
|
CAPRICOR THERAPEUTICS, INC.
|
|
|
|
|
|
Date: November 12, 2020
|
By:
|
/s/ Linda Marbán, Ph.D.
|
|
|
|
Linda Marbán, Ph.D.
|
|
|
|
Chief Executive Officer
|
|
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From Apr 2024 to May 2024
Capricor Therapeutics (NASDAQ:CAPR)
Historical Stock Chart
From May 2023 to May 2024